The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1723-1731

  Sørensen, Michael ^a   Frisch, Kim ^a   Bender, Dirk ^a   Keiding, Susanne ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cirrhosis; FDGal; Hepatobiliary cancer; Molecular imaging; Nuclear hepatology

Indexed keywords

2 DEOXY 2 FLUOROGALACTOSE F 18; ANTINEOPLASTIC AGENT; TRACER; UNCLASSIFIED DRUG; 2 DEOXY 2 FLUOROGALACTOSE; 2-DEOXY-2-FLUOROGALACTOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FUCOSE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; METABOLISM; RADIOFREQUENCY ABLATION; STEREOTACTIC BODY RADIATION THERAPY; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA, HEPATOCELLULAR; FEASIBILITY STUDIES; FEMALE; FUCOSE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOACTIVE TRACERS; RETROSPECTIVE STUDIES;

EID: 80455155185     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1831-z     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37.
4. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104. (Pubitemid 351171046)
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
6. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
7. Lim JH, Kim EY, Lee WJ, Lim HK, Do YS, Choo IW, et al. Regenerative nodules in liver cirrhosis: findings at CT during arterial portography and CT hepatic arteriography with histopathologic correlation. Radiology 1999;210:451-8. (Pubitemid 29055315)
8. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-7.
9. Brancatelli G, Federle MP, Ambrosini R, Lagalla R, Carriero A, Midiri M, et al. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 2007;61:57-69. (Pubitemid 46038025)
10. Valls C, Cos M, Figuera J, Andía E, Ramos E, Sánchez A, et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual-phase helical CT. AJR Am J Roentgenol 2004;182:1011-7. (Pubitemid 38391666)
11. Willat JH, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247:311-30.
12. Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2):S178-192.
13. Delbeke D, Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB 2005;7:166-79. (Pubitemid 41535846)
14. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-7. (Pubitemid 30262739)
15. Wudel Jr LJ, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-26.
16. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-8. (Pubitemid 39490173)
17. Ho CL, Yu S C H, Yeung D W C. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-21.
18. Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, et al. Comparison of (11) C-acetate positron emission tomography and (67) gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int 2006;26:920-7. (Pubitemid 44323409)
19. Ho C, Chen S, Yeung D W C, Cheng T K C. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-9. (Pubitemid 46909918)
20. Park JW, Kim JH, Kim SK, Kang W, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-21.
21. Hwang KH, Choi DJ, Lee SY, Lee MK, Choe W. Evaluation of patients with hepatocellular carcinomas using [(11) C]acetate and [(18) F]FDG PET/CT: A preliminary study. Appl Radiat Isot 2009;67:1195-8.
22. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [(18) F]fluorocholine: preliminary comparison with [(18) F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285-9. (Pubitemid 44630783)
23. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 2008;49:1245-8.
24. Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med 2009;50:1441-7.
25. Ishiwata K, Yamaguchi K, Kameyama M, Fukuda H, Tada M, Matsuzawa T, et al. 2-Deoxy-2-[18F]fluoro-D-galactose as an in vivo tracer for imaging galactose metabolism in tumors with positron emission tomography. Int J Rad Appl Instrum B 1989;16:247-54. (Pubitemid 19094757)
26. Paul R, Aho K, Bergman J, Haaparanta M, Kulmala J, Reissell A, et al. Imaging of rats with mammary cancer with two 2-deoxy-2-[18F]fluoro-D-hexoses. Int J Rad Appl Instrum B 1989;16:449-53. (Pubitemid 19213885)
27. Ishiwata K, Takahashi T, Iwata R, Tomura M, Tada M, Itoh J, et al. Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model. Int J Rad Appl Instrum B 1992;19:611-8.
28. Fukuda H, Takashi J, Fujiwara T, Yamaguchi K, Abe Y, Kubota K, et al. High accumulation of 2-deoxy-fluorine-18-fluoro-D-galactose by well-differentiated hepatomas of mice and rats. J Nucl Med 1993;34:780-6. (Pubitemid 23141557)
29. Sørensen M, Munk OL, Mortensen FV, Olsen AK, Bender D, Bass L, et al. Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxy-galactose positron emission tomography. Am J Physiol Gastrointest Liver Physiol 2008;295:G27-36.
30. Sørensen M. Determination of hepatic galactose elimination capacity using 2-[18F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model. Scand J Gastroenterol 2011;46:98-103.
31. Frisch K, Bender D, Hansen SB, Keiding S, Sørensen M. Nucleophilic radiosynthesis of 2-[18F]fluoro-2-deoxy-D-galactose from Talose triflate and biodistribution in a porcine model. Nucl Med Biol In press 2011.
32. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.